Daiichi Sankyo Healthcare Launches LINE Official Account for 'Norlevo®' Emergency Contraceptive and Adds English Support to Brand Site

Daiichi Sankyo Healthcare Co., Ltd. has launched an official LINE account for 'Norlevo®' (a pharmacist-supervised medicine), Japan's first OTC emergency contraceptive pill. The account provides comprehensive support from the moment a user needs the medicine to post-dose health management. Designed with privacy in mind, it requires no personal data entry, and notifications do not include terms like 'pregnancy' or 'contraception.'

Key features of the LINE account include a 'Pre-dose Self-check' to confirm if the user meets the requirements for purchase at a pharmacy and a 'Notification Function' that reminds users to take a pregnancy test or see a doctor three weeks after dosage. Self-check results can be saved as images to show at pharmacies.

To support non-native Japanese speakers, the brand site now features English content. Additionally, various materials such as pre-dose check sheets, package inserts, and drug guides are now available in English, Simplified Chinese, Traditional Chinese, Korean, and Portuguese on the product information page.

Norlevo® is a switch-OTC drug expected to prevent pregnancy if taken within 72 hours of unprotected intercourse. When purchasing at a pharmacy, users must receive a consultation from a trained pharmacist and take the pill in their presence. Purchase does not require partner or parental consent, and there is no age limit. The manufacturer's suggested retail price is 6,800 yen (excluding tax) per pill.

According to a company survey, approximately 20% of women aged 18 to 49 have experienced a risk of unintended pregnancy. Daiichi Sankyo Healthcare aims to continue its efforts to promote the concept of 'deciding for one's own body' and to improve the environment for accessing emergency contraception through proper information provision.